Follow
Dan Luo
Dan Luo
Verified email at uky.edu
Title
Cited by
Cited by
Year
Inhibition of alpha-synuclein aggregation by multifunctional dopamine agonists assessed by a novel in vitro assay and an in vivo Drosophila synucleinopathy model
D Yedlapudi, GS Joshi, D Luo, SV Todi, AK Dutta
Scientific reports 6 (1), 38510, 2016
572016
Development of a Highly Potent D2/D3 Agonist and a Partial Agonist from Structure–Activity Relationship Study of N6-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N6-propyl …
B Das, S Vedachalam, D Luo, T Antonio, MEA Reith, AK Dutta
Journal of medicinal chemistry 58 (23), 9179-9195, 2015
412015
A novel iron (II) preferring dopamine agonist chelator D-607 significantly suppresses α-syn-and MPTP-induced toxicities in vivo
B Das, S Rajagopalan, GS Joshi, L Xu, D Luo, JK Andersen, SV Todi, ...
Neuropharmacology 123, 88-99, 2017
322017
Synthetic Studies of Neoclerodane Diterpenes from Salvia divinorum: Design, Synthesis, and Evaluation of Analogues with Improved Potency and G-protein …
RS Crowley, AP Riley, AF Alder, RJ Anderson III, D Luo, S Kaska, ...
ACS chemical neuroscience 11 (12), 1781-1790, 2020
262020
Novel multifunctional dopamine D2/D3 receptors agonists with potential neuroprotection and anti-alpha synuclein protein aggregation properties
D Luo, H Sharma, D Yedlapudi, T Antonio, MEA Reith, AK Dutta
Bioorganic & medicinal chemistry 24 (21), 5088-5102, 2016
262016
Targeting alpha synuclein and amyloid beta by a multifunctional, brain-penetrant dopamine D2/D3 agonist D-520: Potential therapeutic application in Parkinson’s disease with …
D Yedlapudi, L Xu, D Luo, GB Marsh, SV Todi, AK Dutta
Scientific Reports 9 (1), 19648, 2019
142019
Design, synthesis, and preliminary evaluation of a potential synthetic opioid rescue agent
SL Hedrick, D Luo, S Kaska, KK Niloy, K Jackson, R Sarma, J Horn, ...
Journal of Biomedical Science 28, 1-18, 2021
122021
The Salvinorin analogue, Ethoxymethyl ether Salvinorin B, promotes Remyelination in preclinical models of multiple sclerosis
KF Paton, K Robichon, N Templeton, L Denny, A Al Abadey, D Luo, ...
Frontiers in neurology 12, 782190, 2021
102021
Xylazine suppresses fentanyl consumption during self-administration and induces a unique sex-specific withdrawal syndrome that is not altered by naloxone in rats.
SN Khatri, S Sadek, PT Kendrick Jr, EO Bondy, M Hong, S Pauss, D Luo, ...
Experimental and Clinical Psychopharmacology, 2023
72023
A journey through diastereomeric space: the design, synthesis, in vitro and in vivo pharmacological activity, and molecular modeling of novel potent diastereomeric MOR agonists …
DR Chambers, A Sulima, D Luo, TE Prisinzano, A Goldberg, B Xie, L Shi, ...
Molecules 27 (19), 6455, 2022
72022
The multifunctional dopamine D2/D3 receptor agonists also possess inhibitory activity against the full-length tau441 protein aggregation
I Ziu, I Rettig, D Luo, A Dutta, TM McCormick, C Wu, S Martic
Bioorganic & medicinal chemistry 28 (18), 115667, 2020
72020
Discovery of a potent highly biased MOR partial agonist among diastereomeric C9-hydroxyalkyl-5-phenylmorphans
JA Lutz, A Sulima, ES Gutman, EW Bow, D Luo, S Kaska, TE Prisinzano, ...
Molecules 28 (12), 4795, 2023
62023
Dopamine agonists in treatment of Parkinson's disease: an overview
D Luo, M Reith, AK Dutta
Diagnosis and Management in Parkinson's Disease, 445-460, 2020
62020
Sex differences in kappa opioid receptor agonist mediated attenuation of chemotherapy-induced neuropathic pain in mice
KF Paton, D Luo, AC La Flamme, TE Prisinzano, BM Kivell
Frontiers in Pharmacology 13, 813562, 2022
52022
Structure-activity studies of PTPRD phosphatase inhibitors identify a 7-cyclopentymethoxy illudalic acid analog candidate for development
IM Henderson, F Zeng, NH Bhuiyan, D Luo, M Martinez, J Smoake, F Bi, ...
Biochemical pharmacology 195, 114868, 2022
32022
A MOR Antagonist with High Potency and Antagonist Efficacy among Diastereomeric C9-Alkyl-Substituted N-Phenethyl-5-(3-hydroxy)phenylmorphans
DR Chambers, A Sulima, D Luo, TE Prisinzano, AE Jacobson, KC Rice
Molecules 28 (14), 5411, 2023
12023
Synthesis and Pharmacological Evaluation of Enantiopure N-Substituted Ortho-c Oxide-Bridged 5-Phenylmorphans
F Li, TA Kopajtic, JL Katz, D Luo, TE Prisinzano, GH Imler, JR Deschamps, ...
Molecules 27 (24), 8808, 2022
12022
Functional Activity of Enantiomeric Oximes and Diastereomeric Amines and Cyano Substituents at C9 in 3-Hydroxy-N-phenethyl-5-phenylmorphans
HG Roth, M Das, A Sulima, D Luo, S Kaska, TE Prisinzano, AT Kerr, ...
Molecules 29 (9), 1926, 2024
2024
Potent MOR Agonists from 2′-Hydroxy-5, 9-dimethyl-N-phenethyl Substituted-6, 7-benzomorphans and from C8-Hydroxy, Methylene and Methyl Derivatives of N-Phenethylnormetazocine
M Das, GW Ward, A Sulima, D Luo, TE Prisinzano, GH Imler, AT Kerr, ...
Molecules 28 (23), 7709, 2023
2023
KAPPA OPIOID RECEPTOR AGONISTS MODULATE THE ANTI-INFLAMMATORY ACTIONS OF MICROGLIA AND PROMOTE OLIGODENDROCYTE MATURATION AND MYELIN REPAIR IN PRECLINICAL MODELS OF MULTIPLE …
B Kivell, R Bibi, B Pengelly, R Van De Wetering, K Paton, D Luo, ...
IBRO Neuroscience Reports 15, S592, 2023
2023
The system can't perform the operation now. Try again later.
Articles 1–20